EP3059309B1 - Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same - Google Patents
Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same Download PDFInfo
- Publication number
- EP3059309B1 EP3059309B1 EP14853414.2A EP14853414A EP3059309B1 EP 3059309 B1 EP3059309 B1 EP 3059309B1 EP 14853414 A EP14853414 A EP 14853414A EP 3059309 B1 EP3059309 B1 EP 3059309B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- galactose
- hydrolase
- agarooligosaccharide
- agarotriose
- agarose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000936 Agarose Polymers 0.000 title claims description 46
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 title description 44
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 title description 29
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical compound O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 title description 25
- 238000004519 manufacturing process Methods 0.000 title description 14
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 title description 8
- IBZYPBGPOGJMBF-UHFFFAOYSA-N 3,6 anhydrogalactose Natural products CCC=CCC1C(CC(=O)NC(C(C)CC)C(O)=O)CCC1=O IBZYPBGPOGJMBF-UHFFFAOYSA-N 0.000 title description 4
- 108090000604 Hydrolases Proteins 0.000 claims description 97
- 239000000758 substrate Substances 0.000 claims description 42
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 41
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 241000607284 Vibrio sp. Species 0.000 claims description 21
- 108010045649 agarase Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 230000003301 hydrolyzing effect Effects 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 229930182830 galactose Natural products 0.000 claims description 11
- 102000004157 Hydrolases Human genes 0.000 description 89
- 102000004190 Enzymes Human genes 0.000 description 39
- 108090000790 Enzymes Proteins 0.000 description 39
- 230000000694 effects Effects 0.000 description 21
- 102000005936 beta-Galactosidase Human genes 0.000 description 16
- 108010005774 beta-Galactosidase Proteins 0.000 description 16
- 230000002255 enzymatic effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000007795 chemical reaction product Substances 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001170685 Saccharophagus degradans 2-40 Species 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 241000195493 Cryptophyta Species 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101710110830 Beta-agarase Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-HEJLOQJISA-N beta-D-galactopyranosyl-(1->4)-D-galactopyranose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-HEJLOQJISA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 3
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 3
- 229960000511 lactulose Drugs 0.000 description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 3
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 108010046109 neoagarobiose hydrolase Proteins 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206671 Gelidium amansii Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241001670248 Saccharophagus degradans Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01082—Exo-poly-alpha-galacturonosidase (3.2.1.82)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01081—Beta-agarase (3.2.1.81)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01159—Alpha-neoagaro-oligosaccharide hydrolase (3.2.1.159)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the present invention relates to a novel ⁇ -agarooligosaccharide hydrolase having hydrolytic activity for agarooligosaccharides and to a method of producing 3,6-anhydro-L-galactose and galactose from agarose by using the same.
- algae Compared to plant biomass currently used in many areas, algae have a lower content of recalcitrant components, such as lignin to use. Therefore, algae are advantageous in that they can be converted much more easily into a monosaccharide which is a substrate for producing bioenergy and biochemicals. Also, by not using food resources, algae are free from the problem of using food resources in producing energy. For these reasons, algae are receiving attention as important biomass in an aspect of the production of biochemicals including alternative energy.
- red algae e.g., Gelidium amansii
- agarooligosaccharides which exhibit excellent physiological activity such as antioxidation, anti-inflammation, anti-cancer, anti-allergy, whitening, and moisturization, as a component, such that it is usefully employed in pharmaceutical and cosmetic fields
- U.S. Patent No. 76622291 by Tomono et al. (2009 ); U.S. Patent No. 691143282 by Enoki et al. (2005 ) U.S. Patent No. 76622291 by Tomono et al. (2009 ); U.S. Patent No. 691143282 by Enoki et al. (2005 )
- red algae contain agarose which is a polymer having neoagarobiose (i.e. 3,6-anhydro-L-galactose and D-galactose bonded by an ⁇ -1,3-linkage) as a basic unit that is connected with another unit by a ⁇ -1,4-linkage.
- neoagarobiose i.e. 3,6-anhydro-L-galactose and D-galactose bonded by an ⁇ -1,3-linkage
- the present inventors empirically proved the fact that the physiological functionality of 3,6-anhydro-L-galactose ( Yun et al (2013) Appl Microbiol Biotechnol. 97(7):2961-70 ).
- Agarose is depolymerized by an exo-type Aga50D enzyme after a chemical pretreatment into neoagarobiose and agarotriose (D-galactose- ⁇ -1,4 linkage-3,6-anhydro-L-galactose- ⁇ -1,3 linkage-D-galactose) which are main reaction products. Then, the neoagarobiose is ultimately hydrolyzed into 3,6-anhydro-L-galactose and D-galactose by Sd NABH (Korean Patent No. 10-1293668 ), which is an ⁇ -neoagarobiose hydrolase.
- Sd NABH Korean Patent No. 10-1293668
- agarotriose produced using a chemically pretreated substrate cannot be ultimately decomposed into 3,6-anhydro-L-galactose and D-galactose and remains as a reaction residue.
- the present invention is directed to providing a method of improving efficiency of agarose saccharification using a novel enzyme having hydrolytic activity for agarooligosaccharides.
- the present invention is also directed to providing a method of producing galactose using a novel enzyme having hydrolytic activity for agarooligosaccharides.
- the present invention provides a composition for agarose saccharification comprising an agarase; a ⁇ -agarooligosaccharide hydrolase having hydrolytic activity for agarotriose and represented by an amino acid sequence of SEQ ID NO:1; and an ⁇ -neoagarobiose hydrolase.
- the present invention also provides a method of saccharifying agarose by reacting a substrate and a composition for agarose saccharification according to the present invention, wherein the substrate is selected from the group consisting of agarose, agarotriose, and neoagarobiose.
- the present invention also provides a composition for producing galactose comprising a ⁇ -agarooligosaccharide hydrolase having hydrolytic activity for agarotriose, agaropentaose, or agaroheptaose and represented by an amino acid sequence of SEQ ID NO:1.
- the present invention provides a method of producing galactose by reacting a substrate and the ⁇ -agarooligosaccharide hydrolase of the present invention, wherein the substrate is selected from the group consisting of agarotriose, agaropentaose and agaroheptaose.
- the present invention is effective in improving the production yield of 3,6-anhydro-L-galactose and D-galactose from agarose, in other words, saccharification yield, by utilizing a ⁇ -agarooligosaccharide hydrolase showing activity toward agarotriose hydrolysis to galactose and neoagarobiose.
- the present invention relates to a composition for agarose saccharification comprising an agarase; a ⁇ -agarooligosaccharide hydrolase having hydrolytic activity for agarotriose and represented by an amino acid sequence of SEQ ID NO:1; and a neoagarobiose hydrolase.
- composition for agarose saccharification of the present invention is characterized in that agarotriose, which used to remain unhydrolyzed in the conventional art, is effectively hydrolyzed such that the production efficiency of 3,6-anhydro-L-galactose and D-galactose from agarose (i.e. an efficiency of agarose saccharification) is significantly improved by utilizing a ⁇ -agarooligosaccharide hydrolase which hydrolyzes agarotriose that is a product of agarooligosaccharide hydrolysis into neoagarobiose and D-galactose for agarose saccharification.
- checked results of reducing equivalents from a DNS method show that the rate of saccharification is about 20 % when an agarose is only pretreated, and that the rate increases up to 50 % when a conventional enzymatic treatment (i.e. a treatment with agarase and neoagarobiose hydrolase) is employed.
- a conventional enzymatic treatment i.e. a treatment with agarase and neoagarobiose hydrolase
- the rate of saccharification is 70 %.
- the ⁇ -agarooligosaccharide hydrolase does not exhibit activity that a ⁇ -galactosidase reportedly shows. Instead, by acting on a non-reducing end of not just agarotriose but also of various agarooligosaccharides (n) such as agaropentaose and agaroheptaose, the ⁇ -agarooligosaccharide hydrolase can hydrolyze agarooligosaccharide into D-galactose and neoagarobiose (n-1).
- the ⁇ -agarooligosaccharide hydrolase may originate from Vibrio sp. EJY3 but is not limited thereto.
- the ⁇ -agarooligosaccharide hydrolase encompasses not only the amino acid sequence represented by SEQ ID NO: 1 but also a protein as a mutated protein of the enzyme with one or more of substitution, deletion, transposition, addition, etc. that has the hydrolytic activity for agarotriose in the scope of the enzyme of the present invention and, preferably, includes an amino acid sequence having a sequence identity of 80 % or more, 85 % or more, 90 % or more, 93 % or more, 94 % or more, 95 % or more, 96 % or more, 97 % or more, 98 % or more, and 99 % or more with the amino acid sequence disclosed in SEQ ID NO: 1 (also referred to as 'AOH').
- a polypeptide having a certain percentage e.g. 80 %, 85 %, 90 %, 95 %, or 99 %) of sequence identity with respect to another sequence signifies that, when aligning the two sequences and comparing them, their amino acid residues are mutually the same by the above ratio.
- the alignment and percentage homology (or identity) may be determined using any suitable software program known in the art, such as those disclosed in the literature [ CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel et al. (eds) 1987 Supplement 30 section 7.7.18 )].
- Preferred programs include GCG Pileup program, FASTA ( Pearson et al. 1988 Proc. Natl Acad.
- BLAST BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med. (NCIB NLM NIH), Bethesda, MD , and Altschul et al. 1997 NAR25:3389-3402 ).
- Another preferred alignment program is ALIGN Plus (Scientific and Educational Software, PA), which preferably uses default parameters.
- TFASTA Data Searching Program is usable in Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison, WI).
- protein and “polypeptide” are used interchangeably herein.
- a conventional one-letter or three-letter code is used herein for amino acid residues.
- the term "recombinant” signifies that the cells, the nucleic acids, the proteins, or the vectors were modified by the introduction of heterologous nucleic acids or proteins, or the modification by alteration of the natural nucleic acid or proteins, or, alternatively, the term may refer to cells that originated from the modified cells.
- a recombinant cell expresses a gene that is not seen in the inherent (non-recombinant) form of the cell, or, alternatively, it expresses an original gene that is expressed abnormally or is not expressed at all.
- nucleic acid encompasses a single-strand or double-strand DNA, RNA, and chemical variants thereof.
- Nucleic acid and polynucleotide may be used interchangeably herein. Since the genetic code is degenerate, one or more codons may be used to encode a particular amino acid, and the present invention encompasses a polynucleotide encoding a particular amino acid sequence.
- introduction used for inserting a nucleic acid sequence into a cell refers to "transfection,” “transformation,” or “transduction,” and includes a reference to an integration into eukaryotic or prokaryotic cells of the nucleic acid sequence.
- the nucleic acid sequence is integrated into the genome (e.g. chromosome, plasmid, plastid, or mitochondrial DNA) of the cell to be converted to an autonomous replicon or transiently expressed.
- the ⁇ -agarooligosaccharide hydrolase may be transcribed or translated not just in a region in upstream or downstream of a coding region of an enzyme but also by a DNA segment, that is, a coding gene, associated with the production of a polypeptide and including intervening sequences between individual coding segments.
- a DNA segment that is, a coding gene, associated with the production of a polypeptide and including intervening sequences between individual coding segments.
- the transcription or translation may be achieved by the sequence of SEQ ID NO: 2 but not limited thereto.
- the ⁇ -agarooligosaccharide hydrolase may be isolated from a supernatant of a Vibrio sp. EJY3 culture and purified, and, by utilizing recombinant genetic engineering techniques, the ⁇ -agarooligosaccharide hydrolase can be produced and isolated by stains other than Vibrio sp. EJY3, artificial chemical synthesis methods, or the like.
- the ⁇ -agarooligosaccharide hydrolase may be purified using a HisTrap HP column and a HisTrap FF column. According to one embodiment, the molecular weight of the purified ⁇ -agarooligosaccharide hydrolase may be about 90 kDa, according to the results of SDS-PAGE analysis.
- the ⁇ -agarooligosaccharide hydrolase is an enzyme that belongs to GH family 2, and when compared for activity with other ⁇ -galactosidases in the GH family 2, the reported conventional ⁇ -galactosidase does not exhibit the enzymatic activity of hydrolyzing agarotriose into D-galactose and neoagarobiose.
- the ⁇ -agarooligosaccharide hydrolase of the present invention which originates from Vibrio sp. EJY3, may show agarotriose hydrolysis activity.
- the ⁇ -agarooligosaccharide hydrolase may exhibit optimal hydrolytic activity on agarotriose in a temperature range of about 30 to 40°C and a pH range of about 5 to 9.6.
- composition for agarose saccharification of the present invention includes an agarase that hydrolyzes agarooligosaccharide to agarotriose and neoagarobiose, which is a disaccharide.
- an enzyme that breaks the ⁇ -1,4-glycosidic linkage between D-galactose and 3,6-anhydro-L-galactose of agarose may be used.
- the agarase encompasses not only the amino acid sequence represented by SEQ ID NO: 3 but also a protein as a mutant protein of the enzyme with one or more of substitution, deletion, transposition, addition, etc. that has the agarooligosaccharide hydrolytic activity in the scope of the enzyme of the present invention and, preferably, includes an amino acid sequence having a sequence identity of 80 % or more, 85 % or more, 90 % or more, 93 % or more, 94 % or more, 95 % or more, 96 % or more, 97 % or more, 98 % or more, and 99 % or more with the amino acid sequence represented by SEQ ID NO: 3.
- the enzyme may have originated from Saccharophagus degradans 2-40 T but is not limited thereto.
- the agarase may be isolated from a culture supernatant of Saccharophagus degradans 2-40 T and purified, and, by utilizing recombinant genetic engineering techniques, the agarase can be produced and isolated by strains other than Saccharophagus degradans, artificial chemical synthesis methods, or the like.
- a culture supernatant of an edible strain for example, transformed yeast may be used, instead of the agarase.
- composition for agarose saccharification of the present invention includes ⁇ -neoagarobiose hydrolase (referred to as 'sdNABH') that may hydrolyze neoagarobiose into 3,6-anhydro-L-galactose and D-galactose.
- 'sdNABH' ⁇ -neoagarobiose hydrolase
- the ⁇ -neoagarobiose hydrolase encompasses not only the amino acid sequence represented by SEQ ID NO: 4 but also a protein as a mutant protein of the enzyme with one or more of substitution, deletion, transposition, addition, etc. that exhibits the neoagarobiose hydrolytic activity in the scope of the enzyme of the present invention and, preferably, includes an amino acid sequence having a sequence identify 80 % or more, 85 % or more, 90 % or more, 93 % or more, 94 % or more, 95 % or more, 96 % or more, 97 % or more, 98 % or more, and 99 % or more with the amino acid sequence represented by SEQ ID NO: 4.
- the enzyme may have originated from Saccharophagus degradans 2-40 T but is not limited thereto.
- the ⁇ -neoagarobiose hydrolase may be isolated from a culture supernatant of Saccharophagus degradans 2-40 T and purified, and, by utilizing recombinant genetic engineering techniques, the ⁇ -neoagarobiose hydrolase can be produced and isolated by strains other than Saccharophagus degradans 2-40 T , artificial chemical synthesis methods, or the like.
- a culture supernatant of an edible strain for example, transformed yeast may be replaced for use.
- the composition for agarose saccharification of the present invention may produce 3,6-anhydro-L-galactose and D-galactose from agarose either by reacting pretreated agarose with an enzyme mixture of the agarase, the ⁇ -agarooligosaccharide hydrolase, and the ⁇ -neoagarobiose hydrolase, or by allowing the agarase, the ⁇ -agarooligosaccharide hydrolase, and the ⁇ -neoagarobiose hydrolase to react sequentially with the pretreated agarose.
- the present invention also relates to a method of saccharifying agarose by reacting a substrate and the composition for agarose saccharification according to the present invention, wherein the substrate is selected from the group consisting of agarose, agarotriose, and neoagarobiose.
- the method of saccharifying agarose of the present invention is characterized in that an agarase (which is an exo-type ⁇ -agarase), a ⁇ -agarooligosaccharide hydrolase, and an ⁇ -neoagarobiose hydrolase are allowed to react with a pretreated agarose to produce 3,6-anhydro-L-galactose and D-galactose.
- an agarase which is an exo-type ⁇ -agarase
- a ⁇ -agarooligosaccharide hydrolase a ⁇ -agarooligosaccharide hydrolase
- an ⁇ -neoagarobiose hydrolase are allowed to react with a pretreated agarose to produce 3,6-anhydro-L-galactose and D-galactose.
- the pretreated agarose refers to an agarose that is treated with a weak acid to produce agarooligosaccharides.
- the weak acid may be one or two or more of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, oxalic acid, and the like.
- the weak acid is used at a concentration in a range of 0.5 to 60 % (w/v). More specifically, it may be used at a concentration in a range of 20 to 40 % (w/v).
- the reaction between the agarose and the weak acid may be carried out in a temperature range of 40 to 150 °C and under conditions of 100 to 200 rpm for a duration ranging from 30 minutes to 6 hours. When the ranges are satisfied, it may be possible to minimize the products of excessive hydrolysis of agarose using the weak acid.
- the resulted reaction products are agarooligosaccharides and may be obtained in a powder form by washing and drying to remove the remaining weak acid and the products of excessive hydrolysis.
- the wash solvent may be a low-grade alcohol having 1 to 6 carbons but not particularly limited thereto.
- an exo-type agarase for the enzymatic hydrolysis of the obtained agarooligosaccharides, an exo-type agarase, a ⁇ -agarooligosaccharide hydrolase, and an ⁇ -neoagarobiose hydrolase are used.
- the agarase hydrolyzes agarooligosaccharides into agarotriose and neoagarobiose
- the ⁇ -agarooligosaccharide hydrolase hydrolyzes agarotriose into D-galactose and neoagarobiose
- the ⁇ -neoagarobiose hydrolase hydrolyzes neoagarobiose into D-galactose and 3,6-anhydro-L-galactose.
- the agarotriose that used to remain during the conventional enzymatic hydrolysis of agarooligosaccharides is hydrolyzed by the ⁇ -agarooligosaccharide hydrolase, resulting in an improvement in the production yield of D-galactose and 3,6-anhydro-L-galactose.
- 3,6-Anhydro-L-galactose and D-galactose may be produced by reacting the pretreated agarose with an enzyme mixture of an agarase, a ⁇ -agarooligosaccharide hydrolase, and an ⁇ -neoagarobiose hydrolase or by allowing the agarase, the ⁇ -agarooligosaccharide hydrolase, and the ⁇ -neoagarobiose hydrolase to react sequentially with the pretreated agarose.
- the reaction between agarooligosaccharides and the enzyme mixture or the sequential reaction between agarooligosaccharides and the enzymes may be carried out in a temperature range of 20 to 40 °C and under conditions ranging from 0 to 200 rpm for a duration ranging from 30 minutes to 7 days. More specifically, they may be carried out in a temperature range of 25 to 35 °C and under conditions ranging from 100 to 150 rpm for a duration ranging from 1 to 4 days.
- agarooligosaccharides When the agarooligosaccharides are in a powder form, it may be dissolved in a conventional buffer solution for use but not limited thereto.
- the present invention also relates to a composition for the production of galactose comprising a ⁇ -agarooligosaccharide hydrolase having hydrolytic activity for agarotriose, agaropentaose or agaroheptaose and represented by the amino acid sequence of SEQ ID NO: 1
- the present invention provides a method of producing galactose by reacting a substrate and the ⁇ -agarooligosaccharide hydrolase of the present invention, wherein the substrate is selected from the group consisting of agarotriose, agaropentaose, and agaroheptaose.
- the ⁇ -agarooligosaccharide hydrolase may originate from Vibrio sp. EJY3 but is not limited thereto.
- the ⁇ -agarooligosaccharide hydrolase produces D-galactose and neoagarobiose from agarotriose, agaropentaose, or agaroheptaose, it can be used for producing D-galactose.
- the enzyme reactions may be carried out in a temperature range of 20 to 40 °C and a pH range of 5 to 9.6.
- Example 1 Determination of enzymatic activity of ⁇ -agarooligosaccharide hydrolase from the crude enzyme extract of Vibrio sp. EJY3
- Vibrio sp. EJY3 has enzymatic activity towards the hydrolysis of agarotriose, a crude extract was obtained and assessed for the activity.
- Vibrio sp. EJY3 was grown up to the mid-exponential phase in a medium including sea salt, then 40 mL of culture medium was centrifuged, cells were disrupted using a sonicator, and the crude extract was obtained.
- PA represents agarose pretreated by a reaction with 3 % acetic acid at 130 °C for 30 minutes
- PAS is a product from a reaction between the pretreated agarose with an exo-type ⁇ agarase (Aga50D) plus an ⁇ -neoagarobiose hydrolase ( Sd NABH)
- PASV is a product obtained when Vibrio sp. EJY3 cruse extract crude extract (or crude enzyme) is added to the PAS.
- EJY3 crude enzyme contained an enzyme that hydrolyzes agarotriose.
- agarotriose was completely hydrolyzed, and reducing equivalents were measured by a reducing sugar quantification method (a DNS method - 50 ⁇ l of a DNS reagent is mixed with 100 ⁇ l of an enzyme reaction product that is diluted 25 times, treated at 95 °C for 5 minutes, and then absorbance is measured at 540 nm).
- a DNS method - 50 ⁇ l of a DNS reagent is mixed with 100 ⁇ l of an enzyme reaction product that is diluted 25 times, treated at 95 °C for 5 minutes, and then absorbance is measured at 540 nm).
- VEJY3_09170 was identified as an enzyme that was classified as a ⁇ -galactosidase based on its genetic sequence and belonged to GH family 2 with many other ⁇ -galactosidases. Then, E. coli rosetta (DE3) was used as a host for the recombinant strain, and pET-21a was used as a vector.
- the culture medium was centrifuged (6000 rpm, 4 °C, 15 minutes) to recover cells, and the recovered cells were suspended in a 20 mM Tris buffer solution (Tris-HCl, 1 M NaCl pH 8), disrupted by sonicator, and then the suspension was centrifuged (16000 rpm, 4 °C, 60 minutes) to separate ⁇ -agarooligosaccharide hydrolasefrom the supernatant and purify using a HisTrap HP column and a HisTrap Q FF column (GE Healthcare, Piscataway, NJ, USA), which was then observed through 8 % SDS-PAGE.
- Tris buffer solution Tris-HCl, 1 M NaCl pH 8
- FIG. 3 is an SDS-PAGE image of a purified ⁇ -agarooligosaccharide hydrolase.
- M represents a protein marker
- Lane 1 represents a ⁇ -agarooligosaccharide hydrolase primarily purified by a HisTrap HP column
- Lane 2 represents the ⁇ -agarooligosaccharide hydrolase secondarily purified by a HisTrap Q FF column.
- the ⁇ -agarooligosaccharide hydrolase was found at a position corresponding to about 90 kDa.
- the optimal conditions consisting only of temperature and pH of a ⁇ -agarooligosaccharide hydrolase were identified.
- Agarotriose (Aglyco, Beijing, China) was used as the substrate, and the results were determined at temperatures of 10, 20, 30, 35, 40, 45, and 50 °C and pH of 4, 5, 6, 7, 8, 9, and 10.
- FIG. 4 shows the optimal temperature and pH results of the ⁇ -agarooligosaccharide hydrolase of the present invention.
- FIG. 4A shows the optimal pH of the ⁇ -agarooligosaccharide hydrolase with respect to an agarotriose substrate
- FIG. 4B shows the optimal temperature of the ⁇ -agarooligosaccharide hydrolase with respect to the agarotriose substrate
- the temperature at which the relative activity for agarotriose reached 50 % ranged from about 30 to 40 °C, and the pH ranged from 5 to 9.6.
- the optimal enzyme activity was attained at 35 °C and pH 7.
- ⁇ -Agarooligosaccharide hydrolase activity with respect to agarotriose, agaropentaose and agaroheptaose substrates was tested under conditions of 35 °C and pH 7, which were optimal conditions identified in the example 3.
- FIG. 6 shows the TLC results of ⁇ -agarooligosaccharide hydrolase activity of the present invention with respect to agarotriose, agaropentaose, and agaroheptaose substrates. As seen in FIG.
- ⁇ -agarooligosaccharide hydrolasehydrolyzed agaropentaose and agaroheptaose as well as agarotriose to produce D-galactose and the ultimate production of 3,6-anhydro-L-galactose and D-galactose was observed when used in combination with ⁇ -agarooligosaccharide hydrolase and ⁇ -neoagarobiose hydrolase ( FIG. 6B ).
- the ⁇ -agarooligosaccharide hydrolase originated from Vibrio sp. EJY3 was found to be an enzyme that belongs to GH family 2 yet shows a new activity different from the previously reported ⁇ -galactosidases.
- the activity of an E . coli -derived ⁇ -galactosidase (Sigma-Aldrich, 3050 spruce street, USA) was tested with respect to each substrate, and the activity of a ⁇ -agarooligosaccharide hydrolasewas tested for the same substrates.
- FIG. 7 shows the activity results of ⁇ -agarooligosaccharide hydrolase with respect to various substrates. Enzyme reactivity was tested with respect to each of lactose, lacto- N -neotetraose, lactulose, 4- ⁇ -galactobiose, and ⁇ -1,3- ⁇ -1,4-galactotriose, and the results reveal that there was no reactivity with respect to any of the substrates.
- FIG. 8 shows the results of E. coli -derived ⁇ -galactosidase hydrolase activity with respect to various substrates. Enzyme reactivity was tested with respect to each of lactose, lacto- N -neotetraose, lactulose, 4- ⁇ -galactobiose, and ⁇ -1,3- ⁇ -1,4-galactotriose, and the already known activity of ⁇ -galactosidase was confirmed ( FIG. 8A ). In addition, enzyme reactivity with respect to each of agarotriose, agaropentaose, and agaroheptaose was tested, and the results confirm that the E. coli- derived ⁇ -galactosidase cannot hydrolyze agarooligosaccharide ( FIG. 8B ).
- 3,6-Anhydro-L-galactose and D-galactose of the present invention can be used as a useful material in food, cosmetic, and pharmaceutical fields.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Description
- The present invention relates to a novel β-agarooligosaccharide hydrolase having hydrolytic activity for agarooligosaccharides and to a method of producing 3,6-anhydro-L-galactose and galactose from agarose by using the same.
- Compared to plant biomass currently used in many areas, algae have a lower content of recalcitrant components, such as lignin to use. Therefore, algae are advantageous in that they can be converted much more easily into a monosaccharide which is a substrate for producing bioenergy and biochemicals. Also, by not using food resources, algae are free from the problem of using food resources in producing energy. For these reasons, algae are receiving attention as important biomass in an aspect of the production of biochemicals including alternative energy.
- Among algae, especially red algae (e.g., Gelidium amansii) is not only a raw material for the production of such bioenergy and biochemicals, but is also reported to contain agarooligosaccharides, which exhibit excellent physiological activity such as antioxidation, anti-inflammation, anti-cancer, anti-allergy, whitening, and moisturization, as a component, such that it is usefully employed in pharmaceutical and cosmetic fields (
U.S. Patent No. 76622291 by Tomono et al. (2009 U.S. Patent No. 691143282 by Enoki et al. (2005 )). - As a main constituent, red algae contain agarose which is a polymer having neoagarobiose (i.e. 3,6-anhydro-L-galactose and D-galactose bonded by an α-1,3-linkage) as a basic unit that is connected with another unit by a β-1,4-linkage. The present inventors empirically proved the fact that the physiological functionality of 3,6-anhydro-L-galactose (Yun et al (2013) Appl Microbiol Biotechnol. 97(7):2961-70). Also reported in relation to the production of the 3,6-anhydro-L-galactose is a preparation process of 3,6-anhydro-L-galactose and D-galactose by a mild chemical pretreatment and enzymatic saccharification to replace chemical treatment methods (Jol et al (1999) Anal Biochem. 268, 213-222; Kim et al (2010) Bull Korean Soc. 31(2) 511-514) that have problems of a very low yield and a high possibility of excessive hydrolysis.
- Agarose is depolymerized by an exo-type Aga50D enzyme after a chemical pretreatment into neoagarobiose and agarotriose (D-galactose-β-1,4 linkage-3,6-anhydro-L-galactose-α-1,3 linkage-D-galactose) which are main reaction products. Then, the neoagarobiose is ultimately hydrolyzed into 3,6-anhydro-L-galactose and D-galactose by SdNABH (Korean Patent No.
10-1293668 - If the remaining agarotriose could be ultimately decomposed into 3,6-anhydro-L-galactose and D-galactose, a larger improvement in the production yield of 3,6-anhydro-L-galactose and D-galactose would be expected. Since endo-type and exo-type β-agarases cannot hydrolyze a substrate such as agarotriose, another approach of decomposing agarotriose into D-galactose and neoagarobiose using a β-galactosidase was tried, but commercially available β-galactosidases did not show hydrolytic activity for agarooligosaccharides.
- The present invention is directed to providing a method of improving efficiency of agarose saccharification using a novel enzyme having hydrolytic activity for agarooligosaccharides.
- The present invention is also directed to providing a method of producing galactose using a novel enzyme having hydrolytic activity for agarooligosaccharides.
- To achieve the above objectives, the present invention provides a composition for agarose saccharification comprising an agarase; a β-agarooligosaccharide hydrolase having hydrolytic activity for agarotriose and represented by an amino acid sequence of SEQ ID NO:1; and an α-neoagarobiose hydrolase.
- The present invention also provides a method of saccharifying agarose by reacting a substrate and a composition for agarose saccharification according to the present invention, wherein the substrate is selected from the group consisting of agarose, agarotriose, and neoagarobiose.
- The present invention also provides a composition for producing galactose comprising a β-agarooligosaccharide hydrolase having hydrolytic activity for agarotriose, agaropentaose, or agaroheptaose and represented by an amino acid sequence of SEQ ID NO:1.
- In addition, the present invention provides a method of producing galactose by reacting a substrate and the β-agarooligosaccharide hydrolase of the present invention, wherein the substrate is selected from the group consisting of agarotriose, agaropentaose and agaroheptaose.
- The present invention is effective in improving the production yield of 3,6-anhydro-L-galactose and D-galactose from agarose, in other words, saccharification yield, by utilizing a β-agarooligosaccharide hydrolase showing activity toward agarotriose hydrolysis to galactose and neoagarobiose.
-
-
FIG. 1 is a TLC image of reaction products for various enzymes (PA: pretreated agarose, PAS: reaction products of Aga50D and SdNABH, with respect to the pretreated agarose, PASV: reaction products of Aga50D, SdNABH, and additionally a Vibrio sp. EJY3 crude enzyme with respect to the pretreated agarose). -
FIG. 2 shows reducing equivalents of PAS and PASV ofFIG. 1 measured by a DNS assay and summarized in a bar graph. -
FIG. 3 is an SDS-PAGE image of a purified β-agarooligosaccharide hydrolase of the present invention. -
FIG. 4 shows optimal temperature and pH results of the β-agarooligosaccharide hydrolase of the present invention.FIG. 4A shows the optimal pH of the β-agarooligosaccharide hydrolase with respect to an agarotriose substrate, andFIG. 4B shows the optimal temperature of the β-agarooligosaccharide hydrolase with respect to the agarotriose substrate (M: protein marker; Lane 1: the β-agarooligosaccharide hydrolase purified primarily using a HisTrap HP column; Lane 2: the β-agarooligosaccharide hydrolase purified secondarily using a HisTrap Q FF column). -
FIG. 5 illustrates the enzymatic activity of β-agarooligosaccharide hydrolase of the present invention on an agarotriose substrate.FIG. 5A is an HPLC result showing changes in the substrate and products in various reaction time between the β-agarooligosaccharide hydrolase and the agarotriose substrate, andFIG. 5B is an HPLC result showing changes in the substrate and products in various reaction time between the β-agarooligosaccharide hydrolase plus α-neoagarobiose hydrolase and the agarotriose substrate. -
FIG. 6 shows the enzymatic activity of β-agarooligosaccharide hydrolase of the present invention on agarotriose, agaropentaose, and agaroheptaose substrates.FIG. 6A shows the reaction products of the β-agarooligosaccharide hydrolase on each substrate by TLC andFIG. 6B shows the reaction products of the β-agarooligosaccharide hydrolase and α-neoagarobiose hydrolase on each substrate by TLC. -
FIG. 7 shows the enzymatic activity of β-agarooligosaccharide hydrolase of the present invention on various substrates (as standards, glucose, and galactose standards were used). -
FIG. 8 shows the enzymatic activity of E. coli-derived β-galactosidase on various substrates (as standards, glucose, and galactose standards were used).FIG. 8A shows the results of an enzyme reaction on each of lactose, lacto-N-neotetraose, lactulose, 4-β-galactobiose, and α-1,3-β-1,4-galactotriose, andFIG. 8B shows the results of an enzyme reaction on each of agarotriose, agaropentaose, and agaroheptaose. -
FIG. 9 is a schematic diagram for showing an agarose saccharification process using the β-agarooligosaccharide hydrolase (β-AOH) of the present invention. - Hereinafter, the components of the present invention will be described in detail.
- The present invention relates to a composition for agarose saccharification comprising an agarase; a β-agarooligosaccharide hydrolase having hydrolytic activity for agarotriose and represented by an amino acid sequence of SEQ ID NO:1; and a neoagarobiose hydrolase.
- The composition for agarose saccharification of the present invention is characterized in that agarotriose, which used to remain unhydrolyzed in the conventional art, is effectively hydrolyzed such that the production efficiency of 3,6-anhydro-L-galactose and D-galactose from agarose (i.e. an efficiency of agarose saccharification) is significantly improved by utilizing a β-agarooligosaccharide hydrolase which hydrolyzes agarotriose that is a product of agarooligosaccharide hydrolysis into neoagarobiose and D-galactose for agarose saccharification.
- According to one embodiment of the present invention, checked results of reducing equivalents from a DNS method show that the rate of saccharification is about 20 % when an agarose is only pretreated, and that the rate increases up to 50 % when a conventional enzymatic treatment (i.e. a treatment with agarase and neoagarobiose hydrolase) is employed. In contrast, when β-agarooligosaccharide hydrolase is additionally treated to hydrolyze agarotriose during the enzymatic treatment, the rate of saccharification is 70 %.
- The β-agarooligosaccharide hydrolase does not exhibit activity that a β-galactosidase reportedly shows. Instead, by acting on a non-reducing end of not just agarotriose but also of various agarooligosaccharides (n) such as agaropentaose and agaroheptaose, the β-agarooligosaccharide hydrolase can hydrolyze agarooligosaccharide into D-galactose and neoagarobiose (n-1).
- The β-agarooligosaccharide hydrolase may originate from Vibrio sp. EJY3 but is not limited thereto.
- The β-agarooligosaccharide hydrolase encompasses not only the amino acid sequence represented by SEQ ID NO: 1 but also a protein as a mutated protein of the enzyme with one or more of substitution, deletion, transposition, addition, etc. that has the hydrolytic activity for agarotriose in the scope of the enzyme of the present invention and, preferably, includes an amino acid sequence having a sequence identity of 80 % or more, 85 % or more, 90 % or more, 93 % or more, 94 % or more, 95 % or more, 96 % or more, 97 % or more, 98 % or more, and 99 % or more with the amino acid sequence disclosed in SEQ ID NO: 1 (also referred to as 'AOH').
- In the present invention, a polypeptide having a certain percentage (e.g. 80 %, 85 %, 90 %, 95 %, or 99 %) of sequence identity with respect to another sequence signifies that, when aligning the two sequences and comparing them, their amino acid residues are mutually the same by the above ratio. The alignment and percentage homology (or identity) may be determined using any suitable software program known in the art, such as those disclosed in the literature [CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel et al. (eds) 1987 )]. Preferred programs include GCG Pileup program, FASTA (Pearson et al. 1988 Proc. Natl Acad. Sci USA 85:2444-2448), and BLAST (BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med. (NCIB NLM NIH), Bethesda, MD, and Altschul et al. 1997 NAR25:3389-3402). Another preferred alignment program is ALIGN Plus (Scientific and Educational Software, PA), which preferably uses default parameters. Another available sequence software program is TFASTA Data Searching Program that is usable in Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison, WI).
- In the present specification, "protein" and "polypeptide" are used interchangeably herein. A conventional one-letter or three-letter code is used herein for amino acid residues.
- In the present invention, when used with respect to cells, nucleic acids, proteins, or vectors, the term "recombinant" signifies that the cells, the nucleic acids, the proteins, or the vectors were modified by the introduction of heterologous nucleic acids or proteins, or the modification by alteration of the natural nucleic acid or proteins, or, alternatively, the term may refer to cells that originated from the modified cells. In other words, for example, a recombinant cell expresses a gene that is not seen in the inherent (non-recombinant) form of the cell, or, alternatively, it expresses an original gene that is expressed abnormally or is not expressed at all.
- In the present specification "nucleic acid" encompasses a single-strand or double-strand DNA, RNA, and chemical variants thereof. "Nucleic acid" and "polynucleotide" may be used interchangeably herein. Since the genetic code is degenerate, one or more codons may be used to encode a particular amino acid, and the present invention encompasses a polynucleotide encoding a particular amino acid sequence.
- The term "introduction" used for inserting a nucleic acid sequence into a cell refers to "transfection," "transformation," or "transduction," and includes a reference to an integration into eukaryotic or prokaryotic cells of the nucleic acid sequence. In this case, the nucleic acid sequence is integrated into the genome (e.g. chromosome, plasmid, plastid, or mitochondrial DNA) of the cell to be converted to an autonomous replicon or transiently expressed.
- The β-agarooligosaccharide hydrolase may be transcribed or translated not just in a region in upstream or downstream of a coding region of an enzyme but also by a DNA segment, that is, a coding gene, associated with the production of a polypeptide and including intervening sequences between individual coding segments. For example, the transcription or translation may be achieved by the sequence of SEQ ID NO: 2 but not limited thereto.
- The β-agarooligosaccharide hydrolase may be isolated from a supernatant of a Vibrio sp. EJY3 culture and purified, and, by utilizing recombinant genetic engineering techniques, the β-agarooligosaccharide hydrolase can be produced and isolated by stains other than Vibrio sp. EJY3, artificial chemical synthesis methods, or the like.
- When using recombinant techniques, factors used for ease of expression of common recombinant proteins, such as genes resistant to antibiotics, and reporter proteins or peptides that can be used for affinity column chromatography may be used, and such techniques are in a scope in which it can be easily conducted by a person of ordinary skill in the technical field to which the present invention belongs. In addition, for example, a culture supernatant of a transformed E. coli may be used, instead of the β-agarooligosaccharide hydrolase of the present invention.
- The β-agarooligosaccharide hydrolase may be purified using a HisTrap HP column and a HisTrap FF column. According to one embodiment, the molecular weight of the purified β-agarooligosaccharide hydrolase may be about 90 kDa, according to the results of SDS-PAGE analysis.
- The β-agarooligosaccharide hydrolase is an enzyme that belongs to
GH family 2, and when compared for activity with other β-galactosidases in theGH family 2, the reported conventional β-galactosidase does not exhibit the enzymatic activity of hydrolyzing agarotriose into D-galactose and neoagarobiose. However, only the β-agarooligosaccharide hydrolase of the present invention, which originates from Vibrio sp. EJY3, may show agarotriose hydrolysis activity. - The β-agarooligosaccharide hydrolase may exhibit optimal hydrolytic activity on agarotriose in a temperature range of about 30 to 40°C and a pH range of about 5 to 9.6.
- In addition, the composition for agarose saccharification of the present invention includes an agarase that hydrolyzes agarooligosaccharide to agarotriose and neoagarobiose, which is a disaccharide.
- As the agarase, an enzyme (referred to as 'Aga50D') that breaks the β-1,4-glycosidic linkage between D-galactose and 3,6-anhydro-L-galactose of agarose may be used.
- The agarase encompasses not only the amino acid sequence represented by SEQ ID NO: 3 but also a protein as a mutant protein of the enzyme with one or more of substitution, deletion, transposition, addition, etc. that has the agarooligosaccharide hydrolytic activity in the scope of the enzyme of the present invention and, preferably, includes an amino acid sequence having a sequence identity of 80 % or more, 85 % or more, 90 % or more, 93 % or more, 94 % or more, 95 % or more, 96 % or more, 97 % or more, 98 % or more, and 99 % or more with the amino acid sequence represented by SEQ ID NO: 3.
- The enzyme may have originated from Saccharophagus degradans 2-40T but is not limited thereto.
- The agarase may be isolated from a culture supernatant of Saccharophagus degradans 2-40T and purified, and, by utilizing recombinant genetic engineering techniques, the agarase can be produced and isolated by strains other than Saccharophagus degradans, artificial chemical synthesis methods, or the like.
- When using recombinant techniques, a culture supernatant of an edible strain, for example, transformed yeast may be used, instead of the agarase.
- In addition, the composition for agarose saccharification of the present invention includes α-neoagarobiose hydrolase (referred to as 'sdNABH') that may hydrolyze neoagarobiose into 3,6-anhydro-L-galactose and D-galactose.
- The α-neoagarobiose hydrolase encompasses not only the amino acid sequence represented by SEQ ID NO: 4 but also a protein as a mutant protein of the enzyme with one or more of substitution, deletion, transposition, addition, etc. that exhibits the neoagarobiose hydrolytic activity in the scope of the enzyme of the present invention and, preferably, includes an amino acid sequence having a sequence identify 80 % or more, 85 % or more, 90 % or more, 93 % or more, 94 % or more, 95 % or more, 96 % or more, 97 % or more, 98 % or more, and 99 % or more with the amino acid sequence represented by SEQ ID NO: 4.
- The enzyme may have originated from Saccharophagus degradans 2-40T but is not limited thereto.
- The α-neoagarobiose hydrolase may be isolated from a culture supernatant of Saccharophagus degradans 2-40T and purified, and, by utilizing recombinant genetic engineering techniques, the α-neoagarobiose hydrolase can be produced and isolated by strains other than Saccharophagus degradans 2-40T, artificial chemical synthesis methods, or the like.
- When using recombinant techniques, a culture supernatant of an edible strain, for example, transformed yeast may be replaced for use.
- The composition for agarose saccharification of the present invention may produce 3,6-anhydro-L-galactose and D-galactose from agarose either by reacting pretreated agarose with an enzyme mixture of the agarase, the β-agarooligosaccharide hydrolase, and the α-neoagarobiose hydrolase, or by allowing the agarase, the β-agarooligosaccharide hydrolase, and the α-neoagarobiose hydrolase to react sequentially with the pretreated agarose.
- The present invention also relates to a method of saccharifying agarose by reacting a substrate and the composition for agarose saccharification according to the present invention, wherein the substrate is selected from the group consisting of agarose, agarotriose, and neoagarobiose.
- The method of saccharifying agarose of the present invention is characterized in that an agarase (which is an exo-type β-agarase), a β-agarooligosaccharide hydrolase, and an α-neoagarobiose hydrolase are allowed to react with a pretreated agarose to produce 3,6-anhydro-L-galactose and D-galactose.
- The pretreated agarose refers to an agarose that is treated with a weak acid to produce agarooligosaccharides.
- The weak acid may be one or two or more of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, oxalic acid, and the like.
- Considering production cost and separation of salt after neutralization by the weak acid, it is preferred that the weak acid is used at a concentration in a range of 0.5 to 60 % (w/v). More specifically, it may be used at a concentration in a range of 20 to 40 % (w/v).
- The reaction between the agarose and the weak acid may be carried out in a temperature range of 40 to 150 °C and under conditions of 100 to 200 rpm for a duration ranging from 30 minutes to 6 hours. When the ranges are satisfied, it may be possible to minimize the products of excessive hydrolysis of agarose using the weak acid.
- The resulted reaction products are agarooligosaccharides and may be obtained in a powder form by washing and drying to remove the remaining weak acid and the products of excessive hydrolysis.
- The wash solvent may be a low-grade alcohol having 1 to 6 carbons but not particularly limited thereto.
- For the enzymatic hydrolysis of the obtained agarooligosaccharides, an exo-type agarase, a β-agarooligosaccharide hydrolase, and an α-neoagarobiose hydrolase are used.
- The agarase hydrolyzes agarooligosaccharides into agarotriose and neoagarobiose, the β-agarooligosaccharide hydrolase hydrolyzes agarotriose into D-galactose and neoagarobiose, and the α-neoagarobiose hydrolase hydrolyzes neoagarobiose into D-galactose and 3,6-anhydro-L-galactose.
- Therefore, the agarotriose that used to remain during the conventional enzymatic hydrolysis of agarooligosaccharides is hydrolyzed by the β-agarooligosaccharide hydrolase, resulting in an improvement in the production yield of D-galactose and 3,6-anhydro-L-galactose.
- 3,6-Anhydro-L-galactose and D-galactose may be produced by reacting the pretreated agarose with an enzyme mixture of an agarase, a β-agarooligosaccharide hydrolase, and an α-neoagarobiose hydrolase or by allowing the agarase, the β-agarooligosaccharide hydrolase, and the α-neoagarobiose hydrolase to react sequentially with the pretreated agarose.
- The reaction between agarooligosaccharides and the enzyme mixture or the sequential reaction between agarooligosaccharides and the enzymes may be carried out in a temperature range of 20 to 40 °C and under conditions ranging from 0 to 200 rpm for a duration ranging from 30 minutes to 7 days. More specifically, they may be carried out in a temperature range of 25 to 35 °C and under conditions ranging from 100 to 150 rpm for a duration ranging from 1 to 4 days.
- When the agarooligosaccharides are in a powder form, it may be dissolved in a conventional buffer solution for use but not limited thereto.
- The present invention also relates to a composition for the production of galactose comprising a β-agarooligosaccharide hydrolase having hydrolytic activity for agarotriose, agaropentaose or agaroheptaose and represented by the amino acid sequence of SEQ ID NO: 1
- Also, the present invention provides a method of producing galactose by reacting a substrate and the β-agarooligosaccharide hydrolase of the present invention, wherein the substrate is selected from the group consisting of agarotriose, agaropentaose, and agaroheptaose.
- The β-agarooligosaccharide hydrolase may originate from Vibrio sp. EJY3 but is not limited thereto.
- Since the β-agarooligosaccharide hydrolase produces D-galactose and neoagarobiose from agarotriose, agaropentaose, or agaroheptaose, it can be used for producing D-galactose.
- The enzyme reactions may be carried out in a temperature range of 20 to 40 °C and a pH range of 5 to 9.6.
- Hereinafter, the present invention will be described in detail with reference to exemplary embodiments. However, the following exemplary embodiments are intended merely to exemplify the present invention, and the scope of the present invention is not limited thereto.
- To confirm that Vibrio sp. EJY3 has enzymatic activity towards the hydrolysis of agarotriose, a crude extract was obtained and assessed for the activity.
- To obtain the crude extract, Vibrio sp. EJY3 was grown up to the mid-exponential phase in a medium including sea salt, then 40 mL of culture medium was centrifuged, cells were disrupted using a sonicator, and the crude extract was obtained. Using agarose as the substrate, the hydrolysis products by β agarase were observed by TLC (composition of a TLC solvent: n-butanol:ethanol:water = 3:1:1 by volume).
- The TLC results of reaction products for various enzymes were shown in
FIG. 1 based on 3,6-anhydro-L-galactose, galactose, neoagarobiose standards. PA represents agarose pretreated by a reaction with 3 % acetic acid at 130 °C for 30 minutes, PAS is a product from a reaction between the pretreated agarose with an exo-type β agarase (Aga50D) plus an α-neoagarobiose hydrolase (SdNABH), and PASV is a product obtained when Vibrio sp. EJY3 cruse extract crude extract (or crude enzyme) is added to the PAS. - As seen in
FIG. 1 , a decrease in agarotriose was observed when Vibrio sp. EJY3 crude enzyme was additionally engaged in the reaction. From this, it could be confirmed that the Vibrio sp. EJY3 crude enzyme contained an enzyme that hydrolyzes agarotriose. - In addition, agarotriose was completely hydrolyzed, and reducing equivalents were measured by a reducing sugar quantification method (a DNS method - 50 µl of a DNS reagent is mixed with 100 µl of an enzyme reaction product that is diluted 25 times, treated at 95 °C for 5 minutes, and then absorbance is measured at 540 nm).
- As shown in
FIG. 2 , an increase in the production yield of 3,6-anhydro-L-galactose and galactose was confirmed. The rate of saccharification when only a pretreatment was performed was about 20 %, but the rate increased up to 50 % when an enzymatic pretreatment was performed. To this, an additional treatment with Vibrio sp. EJY3 crude enzyme resulted in a rate of saccharification of 70 % which was thought to be attributed to an ultimate the agarotriose hydrolysis. - Among the enzymes that were reported in relation to Vibrio sp. EJY3, 8 enzymes that reportedly had activity for an agarase and a β-galactosidase were cloned to produce a recombinant strain, and then each crude enzyme activity for agarotriose was assessed. Among these, only one enzyme (VEJY3_09170) was found to have hydrolytic activity for agarotriose. As confirmed through UniProt (http://www.uniprot.org) and based on full genome sequence data of Vibrio sp. EJY3 that the present inventors revealed for the first time, VEJY3_09170 was identified as an enzyme that was classified as a β-galactosidase based on its genetic sequence and belonged to
GH family 2 with many other β-galactosidases. Then, E. coli rosetta (DE3) was used as a host for the recombinant strain, and pET-21a was used as a vector. A colony that was inoculated on a solid medium having an ampicillin concentration of 50 µg/mL and obtained by transformation was again inoculated into an LB (Luria broth) containing 50 µg/mL ampicillin and then incubated for 12 hours under the conditions of 37 °C and 220 rpm (two 20 mL volumes). Then, it was inoculated into two 3 L Erlenmeyer flasks, each containing 1 L of LB broth, and shaking cultured under the same conditions for 3 hours (OD = 0.8), cooled in ice for 1 hour, and added 0.1 mM IPTG to induce an expression under conditions of 16 °C and 120 rpm for 12 hours. The culture medium was centrifuged (6000 rpm, 4 °C, 15 minutes) to recover cells, and the recovered cells were suspended in a 20 mM Tris buffer solution (Tris-HCl, 1 M NaCl pH 8), disrupted by sonicator, and then the suspension was centrifuged (16000 rpm, 4 °C, 60 minutes) to separate β-agarooligosaccharide hydrolasefrom the supernatant and purify using a HisTrap HP column and a HisTrap Q FF column (GE Healthcare, Piscataway, NJ, USA), which was then observed through 8 % SDS-PAGE. -
FIG. 3 is an SDS-PAGE image of a purified β-agarooligosaccharide hydrolase. M represents a protein marker,Lane 1 represents a β-agarooligosaccharide hydrolase primarily purified by a HisTrap HP column, andLane 2 represents the β-agarooligosaccharide hydrolase secondarily purified by a HisTrap Q FF column. - As shown in
FIG. 3 , the β-agarooligosaccharide hydrolase was found at a position corresponding to about 90 kDa. - The optimal conditions consisting only of temperature and pH of a β-agarooligosaccharide hydrolase were identified. Agarotriose (Aglyco, Beijing, China) was used as the substrate, and the results were determined at temperatures of 10, 20, 30, 35, 40, 45, and 50 °C and pH of 4, 5, 6, 7, 8, 9, and 10.
-
FIG. 4 shows the optimal temperature and pH results of the β-agarooligosaccharide hydrolase of the present invention.FIG. 4A shows the optimal pH of the β-agarooligosaccharide hydrolase with respect to an agarotriose substrate, andFIG. 4B shows the optimal temperature of the β-agarooligosaccharide hydrolase with respect to the agarotriose substrate - As shown in
FIG. 4 , the temperature at which the relative activity for agarotriose reached 50 % ranged from about 30 to 40 °C, and the pH ranged from 5 to 9.6. The optimal enzyme activity was attained at 35 °C andpH 7. - β-Agarooligosaccharide hydrolase activity with respect to agarotriose, agaropentaose and agaroheptaose substrates was tested under conditions of 35 °C and
pH 7, which were optimal conditions identified in the example 3. - When the changes in the substrate and products with respect to a time of reaction between the β-agarooligosaccharide hydrolase and the agarotriose substrate were observed through HPLC (KS-802 column) and TLC (conditions for the TLC solvent: n-Buthanol:EtOH:Water = 3:1:1) analyses, it could be recognized that the β-agarooligosaccharide hydrolase breaks down one molecule of agarooligosaccharide into one molecule of neoagarooligosaccharide and one molecule of D-galactose by hydrolysis (
FIG. 5A ) - Also, when the changes in the substrate and products with respect to the time of reaction between the β-agarooligosaccharide hydrolaseplus α-neoagarobiose hydrolase and the agarotriose substrate were analyzed by HPLC, it could be recognized that 3,6-anhydro-L-galactose and D-galactose were ultimately produced from agarooligosaccharide using the β-agarooligosaccharide hydrolase and α-neoagarobiose hydrolase in combination (
FIG. 5B ). -
FIG. 6 shows the TLC results of β-agarooligosaccharide hydrolase activity of the present invention with respect to agarotriose, agaropentaose, and agaroheptaose substrates. As seen inFIG. 6A , β-agarooligosaccharide hydrolasehydrolyzed agaropentaose and agaroheptaose as well as agarotriose to produce D-galactose, and the ultimate production of 3,6-anhydro-L-galactose and D-galactose was observed when used in combination with β-agarooligosaccharide hydrolase and α-neoagarobiose hydrolase (FIG. 6B ). - When compared with other β-galactosidases that belong to
GH family 2 in terms of activity, the β-agarooligosaccharide hydrolase originated from Vibrio sp. EJY3 was found to be an enzyme that belongs toGH family 2 yet shows a new activity different from the previously reported β-galactosidases. The activity of an E. coli-derived β-galactosidase (Sigma-Aldrich, 3050 spruce street, USA) was tested with respect to each substrate, and the activity of a β-agarooligosaccharide hydrolasewas tested for the same substrates. -
FIG. 7 shows the activity results of β-agarooligosaccharide hydrolase with respect to various substrates. Enzyme reactivity was tested with respect to each of lactose, lacto-N-neotetraose, lactulose, 4-β-galactobiose, and α-1,3-β-1,4-galactotriose, and the results reveal that there was no reactivity with respect to any of the substrates. -
FIG. 8 shows the results of E. coli-derived β-galactosidase hydrolase activity with respect to various substrates. Enzyme reactivity was tested with respect to each of lactose, lacto-N-neotetraose, lactulose, 4-β-galactobiose, and α-1,3-β-1,4-galactotriose, and the already known activity of β-galactosidase was confirmed (FIG. 8A ). In addition, enzyme reactivity with respect to each of agarotriose, agaropentaose, and agaroheptaose was tested, and the results confirm that the E. coli-derived β-galactosidase cannot hydrolyze agarooligosaccharide (FIG. 8B ). - The above results demonstrates that the present invention could improve the product yield and efficiency of agarose saccharification using β-agarooligosaccharide hydrolase, and the schematic view of the saccharification process is as shown in
FIG. 9 . - 3,6-Anhydro-L-galactose and D-galactose of the present invention can be used as a useful material in food, cosmetic, and pharmaceutical fields.
- <110> Korea University Industrial & Academic Collaboration Foundation
- <120> Beta-agarooligosaccharides hydrolase and enzymatic production method of 3,6-anhydro-L-galactose and galactose from agarose by using the same
- <130> X14U13C0108
- <150>
10-2013-0121990
<151> 2013-10-14 - <160> 4
- <170> KopatentIn 2.0
- <210> 1
<211> 806
<212> PRT
<213> Vibrio sp. EJY3 - <400> 1
- <210> 2
<211> 2421
<212> DNA
<213> Vibrio sp. EJY3 - <400> 2
- <210> 3
<211> 747
<212> PRT
<213> Saccharophagus degradans 2-40 - <400> 3
Claims (11)
- A composition for use in agarose saccharification comprising:an agarase;a β-agarooligosaccharide hydrolase having the amino acid sequence of SEQ ID NO:1 and hydrolytic activity for agarotriose; and an α-neoagarobiose hydrolase.
- The composition of claim 1, wherein the agarase has the amino acid sequence of SEQ ID NO: 3.
- The composition of claim 1, wherein the β-agarooligosaccharide hydrolase hydrolyzes agarotriose into D-galactose and neoagarobiose.
- The composition of claim 1, wherein the β-agarooligosaccharide hydrolase is from Vibrio sp. EJY3.
- The composition of claim 1, wherein the α-neoagarobiose hydrolase has the amino acid sequence of SEQ ID NO: 4.
- A method of saccharifying agarose by a reaction between a substrate and the composition selected from any one of claims 1 to 5, wherein the substrate is selected from the group consisting of agarose, agarotriose, and neoagarobiose.
- The method of claim 6, wherein the reaction is carried out in a temperature range of 20 to 40 °C under conditions of 0 to 200 rpm for a duration ranging from 30 minutes to 7 days.
- A composition for producing galactose comprising a β-agarooligosaccharide hydrolase having the amino acid sequence of SEQ ID NO:1 and hydrolytic activity for agarotriose, agaropentaose, or agaroheptaose.
- The composition of claim 8, wherein the β-agarooligosaccharide hydrolase is from Vibrio sp. EJY3.
- A method of producing galactose by a reaction between a substrate and the β-agarooligosaccharide hydrolase of claim 8 or claim 9, wherein the substrate is selected from the group consisting of agarotriose, agaropentaose, and agaroheptaose.
- The method of claim 10, wherein the reaction is carried out in a temperature range of 20 to 40 °C and pH range of 5 to 9.6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130121990A KR101521711B1 (en) | 2013-10-14 | 2013-10-14 | Novel β-agarooligosaccharide hydrolase and enzymatic production method of 3,6-anhydro-L-galactose and galactose from agarose by using the same |
PCT/KR2014/009470 WO2015056923A1 (en) | 2013-10-14 | 2014-10-08 | Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3059309A1 EP3059309A1 (en) | 2016-08-24 |
EP3059309A4 EP3059309A4 (en) | 2017-03-15 |
EP3059309B1 true EP3059309B1 (en) | 2018-05-16 |
Family
ID=52828313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14853414.2A Active EP3059309B1 (en) | 2013-10-14 | 2014-10-08 | Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same |
Country Status (5)
Country | Link |
---|---|
US (1) | US9902983B2 (en) |
EP (1) | EP3059309B1 (en) |
KR (1) | KR101521711B1 (en) |
CN (1) | CN106414728B (en) |
WO (1) | WO2015056923A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101743421B1 (en) | 2015-10-16 | 2017-06-05 | 고려대학교 산학협력단 | Anticariogenic use of 3,6-anhydro-L-galactose |
KR101787331B1 (en) * | 2016-01-19 | 2017-10-19 | 고려대학교 산학협력단 | Thermotolerant agarase and method for producing monomeric sugars using the agarse |
KR101851628B1 (en) * | 2016-04-04 | 2018-04-25 | 고려대학교 산학협력단 | Novel purification method of 3,6-anhydro-L-galactose using microorganisms |
KR101864800B1 (en) | 2016-12-07 | 2018-06-07 | 고려대학교 산학협력단 | Method for preparing anhydrogalactose derived from marine macroalgae |
KR20190008014A (en) * | 2017-07-14 | 2019-01-23 | 고려대학교 산학협력단 | Quantification method of 3,6-anhydro-L-galactose using high-performance liquid chromatography equipped with a refractive index detector |
KR102032799B1 (en) | 2017-11-16 | 2019-10-17 | 고려대학교 산학협력단 | Method for producing agarotriose and prebiotics use thereof |
KR102124590B1 (en) * | 2018-09-06 | 2020-06-19 | 고려대학교 산학협력단 | A method for producing the novel sugar alcohols from red macroalgae |
CN109913504B (en) * | 2019-04-23 | 2021-05-28 | 集美大学 | Method for preparing bioethanol from modified agar |
CN114214377B (en) * | 2021-12-24 | 2024-03-08 | 中国海洋大学 | Phosphatidyl-agar oligosaccharide and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW577743B (en) | 1997-11-11 | 2004-03-01 | Takara Shuzo Co | Drugs, foods or drinks with the use of algae-derived physiologically active substances |
DE60226182T2 (en) | 2001-02-27 | 2009-07-16 | Takara Bio Inc., Otsu | Agarase and gene for it |
CN1239708C (en) * | 2003-06-04 | 2006-02-01 | 中国海洋大学 | Beta-agaropectinase gene aga, its preparation method and application |
CN1224709C (en) * | 2003-06-06 | 2005-10-26 | 中国海洋大学 | Beta-agaropectionase gene aga B, its preparation method and application |
JP5468680B2 (en) * | 2009-03-27 | 2014-04-09 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | Novel alpha-neo agarobiose hydrolase and method for obtaining monosaccharides using the same |
KR101212106B1 (en) * | 2010-04-16 | 2012-12-13 | 제주대학교 산학협력단 | A beta-agarase and a use of the same |
-
2013
- 2013-10-14 KR KR1020130121990A patent/KR101521711B1/en active IP Right Grant
-
2014
- 2014-10-08 WO PCT/KR2014/009470 patent/WO2015056923A1/en active Application Filing
- 2014-10-08 CN CN201480056714.2A patent/CN106414728B/en active Active
- 2014-10-08 EP EP14853414.2A patent/EP3059309B1/en active Active
- 2014-10-08 US US15/029,160 patent/US9902983B2/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
US9902983B2 (en) | 2018-02-27 |
CN106414728A (en) | 2017-02-15 |
KR20150043040A (en) | 2015-04-22 |
US20160265012A1 (en) | 2016-09-15 |
EP3059309A4 (en) | 2017-03-15 |
CN106414728B (en) | 2020-02-07 |
KR101521711B1 (en) | 2015-05-19 |
WO2015056923A1 (en) | 2015-04-23 |
EP3059309A1 (en) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3059309B1 (en) | Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same | |
US9297000B2 (en) | Alpha-neoagarobiose hydrolase and method for obtaining a monosaccharide using same | |
KR101787331B1 (en) | Thermotolerant agarase and method for producing monomeric sugars using the agarse | |
CN114410611A (en) | Kunmu polysaccharide degrading enzyme OUC-BsLam26 and application thereof | |
CN104726435A (en) | Beta-glucosidase mutant, recombinant expression plasmid thereof and transformed engineering strain | |
US10883128B2 (en) | Method of producing gentiobiose or glucose from β-glucan using β-1,6-endoglucanase | |
US20170327854A1 (en) | Methods for cellobiosan utilization | |
CN114214302B (en) | Agarase, coding gene, recombinant vector, host cell, application of agarase, recombinant vector and host cell, and novel agarase oligosaccharide and preparation method of novel agarase | |
CN107779443B (en) | Cellobiohydrolase mutants and uses thereof | |
KR101641173B1 (en) | Method for improving production yield of monomeric sugars using pretreatment of agar by buffer solution | |
WO2016175202A1 (en) | Heat-resistant xylanase | |
CN109929816B (en) | Polysaccharide cleaved monooxygenase MtLPMO9G encoding gene and preparation and application thereof | |
KR101350823B1 (en) | Composition for increasing saccharification efficiency of biomass, method for increasing saccharification efficiency of biomass and method for preparing bioethanol derived from biomass on a large scale using charperone protein | |
CN111979218B (en) | Arthrobacter sp. AW19M34-1 chitin deacetylase mutant | |
JP6315807B2 (en) | Super thermostable endoglucanase belonging to GH family 12 | |
Bulakhov et al. | Properties of Chimeric Polysaccharide Monooxygenase with an Attached Cellulose Binding Module and Its Use in the Hydrolysis of Cellulose-Containing Materials in the Composition of Cellulase Complexes | |
JP7250282B2 (en) | Novel β-Glucosidase, Enzyme Composition Containing Same, and Method for Producing Sugar Solution Using These | |
CN112442488B (en) | Soluble polysaccharide monooxygenase mutant and application thereof | |
CN114107260B (en) | Fucoidan sulfate degrading enzyme OUC-FaFcn1 and application thereof | |
KR102166572B1 (en) | Use of alpha-neoagarooligosaccharide hydrolase from Gayadomonas joobiniege G7 | |
KR102100958B1 (en) | Use of alpha-neoagarooligosaccharide hydrolase from Gayadomonas joobiniege G7 | |
EP3757209A1 (en) | Enzymatic production of levan-based, prebiotic fructooligosaccharides | |
WO2014028774A2 (en) | Cellulose and/or hemicelluloses degrading enzymes from macrophomina phaseolina and uses thereof | |
KR101455720B1 (en) | KRICT PXD2 Enzyme Having Multifunctional β-D-xylosidase Activity | |
WO2018215959A1 (en) | Method for the extraction of recombinant proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160405 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602014025709 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12N0009240000 Ipc: C12N0009400000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170214 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12P 19/14 20060101ALI20170203BHEP Ipc: C12P 19/02 20060101ALI20170203BHEP Ipc: C12N 9/40 20060101AFI20170203BHEP Ipc: C12N 9/38 20060101ALI20170203BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170804 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180122 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 999594 Country of ref document: AT Kind code of ref document: T Effective date: 20180615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014025709 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20180516 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180816 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180816 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180817 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 999594 Country of ref document: AT Kind code of ref document: T Effective date: 20180516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014025709 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190219 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602014025709 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20181008 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20181031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181008 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181008 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180516 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20141008 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180916 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231006 Year of fee payment: 10 |